The clinical trials above used full-length Thymosin Beta-4, not TB-500 specifically
How BPC-157 Works for Spinal Conditions BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids derived from a naturally occurring protein in human gastric juice
Intranasal administration is valued as a non-invasive means of both systemic and local administration with good bioavailability, rapid onset, and targeted effects on the central nervous system [13, 14]
Food, environment, lifestyle and gut function may all influence gene expression, inflammation, mitochondrial function and methylation without changing the DNA sequence
There was a positive trend in the Composite SLE Responder Index in the Intention-to-treat (ITT) cohort, and post-hoc analysis showed that the BILAG secondary endpoint was met for a number of subgroups dosing levels, including low or no steroids, seropositivity, and patients with 2 grade BILAG improvement
Results BPC-157 dose-dependently decreased the number of flinches during phase 1 but did not decrease the number of flinches during phase 2
